Autologous Cell Therapy Market Will Cross US$23.7 Bn by 2024
In the past few decades, the field of autologous cell therapy (ACT) has been witnessed rapid evolution and a surge in research activities aimed at the realization of the potential benefits of use of biosynthetic composites for a variety of human conditions. With successful products such as plasmids for the bulk production of therapeutic proteins, recombinant human insulin, and artificial organs, autologous cell therapy has continued to gain an increasing amount of interest from the scientific community.
View full press release